Creative Planning Purchases 4,561 Shares of Qiagen (NYSE:QGEN)

Creative Planning grew its position in shares of Qiagen (NYSE:QGEN) by 12.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 40,571 shares of the company’s stock after acquiring an additional 4,561 shares during the quarter. Creative Planning’s holdings in Qiagen were worth $1,849,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. CWM LLC boosted its stake in Qiagen by 11.5% during the third quarter. CWM LLC now owns 2,792 shares of the company’s stock worth $127,000 after buying an additional 287 shares during the period. GAMMA Investing LLC boosted its stake in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the period. Handelsbanken Fonder AB boosted its stake in Qiagen by 37.3% during the third quarter. Handelsbanken Fonder AB now owns 73,304 shares of the company’s stock worth $3,340,000 after buying an additional 19,900 shares during the period. Park Avenue Securities LLC bought a new stake in shares of Qiagen during the third quarter worth $304,000. Finally, Massmutual Trust Co. FSB ADV lifted its position in shares of Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

QGEN has been the subject of several research analyst reports. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research report on Thursday, October 17th. Finally, Robert W. Baird lifted their price objective on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Qiagen currently has a consensus rating of “Moderate Buy” and an average price target of $50.12.

Qiagen Stock Performance

Shares of Qiagen stock opened at $41.80 on Tuesday. The company has a market capitalization of $9.54 billion, a PE ratio of 139.09, a P/E/G ratio of 3.17 and a beta of 0.39. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77. The company has a 50-day simple moving average of $44.58 and a two-hundred day simple moving average of $43.56. Qiagen has a one year low of $34.74 and a one year high of $47.44.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. The business had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm’s revenue was down .2% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. Research analysts expect that Qiagen will post 2.15 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.